Axxam and Boehringer Ink Two Drug Research Agreements
Deals cover identification, validation, assay development, HTS, and lead optimizations.!--h2>
Axxam signed two drug research collaboration agreements with Boehringer Ingelheim. The first collaboration agreement aims to identify and validate therapeutic targets with subsequent assay development, high-throughput screening (HTS), and lead optimizations.
The second agreement covers the transfer of protein material and a corresponding specific functional assay for HTS to Boehringer Ingelheim.
Axxam will receive fees as the collaboration progresses and milestone payments for successful exploitation of results through development stages.